University Of Pecs
- Address
- lock Available on a paid plan
Cardiovascular Diseases
At the University Of Pecs, clinical research in cardiovascular diseases focuses on major conditions such as acute coronary syndrome, atrial fibrillation, acute myocardial infarction, and different forms of heart failure. These studies are designed to test new treatments, reduce the risk of serious events, and improve long-term outcomes for patients with high cardiovascular risk.
- Testing new approaches to lower the risk of cardiovascular death, stroke, and recurrent heart events
- Evaluating therapies for atrial fibrillation and stroke prevention
- Studying treatment options for heart failure with reduced or preserved ejection fraction
Research at this site also includes efforts to improve safety in patients needing urgent procedures while taking blood-thinning medicines, highlighting a strong focus on practical care in real-world cardiac medicine.
Digestive System Diseases
The site is conducting studies in digestive system diseases with attention to hepatic encephalopathy and ulcerative colitis. These trials aim to assess whether new therapies can better control symptoms, delay complications, and support patients living with chronic gastrointestinal and liver-related conditions.
- Investigating treatments to delay worsening of hepatic encephalopathy
- Comparing therapies for moderately to severely active ulcerative colitis
- Exploring ways to improve disease control and patient quality of life
This work reflects a broader interest in finding more effective and better-tolerated options for long-term digestive and liver disease management.
Hemic and Lymphatic Diseases
Clinical trials in hemic and lymphatic diseases at this educational institution include research on acute myeloid leukemia, multiple myeloma, and chronic lymphocytic leukemia. The main goal is to evaluate new treatment combinations and personalized approaches that may improve disease control and patient outcomes in blood cancers.
- Assessing treatment options for acute myeloid leukemia with IDH1 mutation
- Studying new combinations for relapsed or refractory multiple myeloma
- Customizing therapy for chronic lymphocytic leukemia to improve effectiveness and tolerability
The research emphasizes both safety and effectiveness, with a strong interest in tailoring care to individual patient needs.
Hormonal Diseases
In hormonal diseases, the University Of Pecs is involved in trials for hypoparathyroidism. These studies are focused on improving control of calcium balance and testing whether new treatment options can better support patients with this chronic endocrine disorder.
- Evaluating therapies for chronic hypoparathyroidism
- Measuring effects on serum calcium and symptom control
- Seeking more reliable long-term management options for endocrine disease
This area of research is centered on helping patients achieve more stable disease control with fewer treatment burdens.
Neoplasms
The neoplasms portfolio at this site includes trials in acute myeloid leukemia, multiple myeloma, and chronic lymphocytic leukemia. Research is aimed at testing innovative cancer treatments, improving response rates, and supporting better outcomes for people with difficult-to-treat blood cancers.
- Studying new therapies for acute myeloid leukemia and treatment-naive patients
- Evaluating combination strategies in multiple myeloma
- Assessing tailored treatment approaches for chronic lymphocytic leukemia
This cancer research reflects a strong commitment to advancing more effective and better-targeted care in hematologic oncology.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 8 therapeutic areas and 15 of 65 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 53 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 6 by active trials.
- 1AstraZeneca AB1active
lock +5 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Merck Sharp & Dohme LLC8trials
lock +3 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 332 other sites in Hungary
Therapeutic Area Benchmark — Hungary
Select a therapeutic area to compare against other sites in Hungary.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Hungary
Market Share
Country: Hungary
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in University Of Pecs
lock Showing 1 of 26 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 2, Multicenter, Multi Arm, Study to Evaluate MK-1308A (Coformulated quavonlimab (MK-1308)/pembrolizumab) Versus Other Treatments in Participants with Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer: (MK-1308A-008) | Merck Sharp & Dohme LLC | Phase IV | Not Recruiting | Jun 2021 | Jul 2026 |
IMP list
lock Showing 1 of 65 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Pembrolizumab | 8 | Unknown | 2018-12-13 | 2024-06-13 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.